失眠药物治疗市场 - 全球产业规模、份额、趋势、机会和预测，按药物、按治疗、按配销通路、按地区和竞争细分，2020-2030 年

2024 年全球失眠药物治疗市场价值为 38.1 亿美元，预计到 2030 年将达到 53.3 亿美元，年复合成长率(CAGR) 为 5.73%。由于全球睡眠障碍盛行率不断上升，市场正在经历显着增长。压力增加、生活方式改变以及人口老化加剧等因素加剧了对失眠药物治疗的需求。该市场包括广泛的处方药和非处方药，包括苯二氮平类药物、非苯二氮平催眠药、褪黑激素受体激动剂和食慾素受体拮抗剂。製药公司正致力于开发更安全、更有效的药物，以解决与传统睡眠辅助药物的依赖和副作用相关的问题。监管部门对新疗法的批准和药物配方的创新进一步刺激了市场成长，为患者提供了更高的疗效并减少了副作用。

人们越来越意识到不治疗失眠症会带来长期健康风险，导致失眠的诊断增多，对处方解决方案的需求也日益增长。缓释和双重作用配方的创新可确保整晚的持续睡眠，进而改善治疗效果。此外，个人化医疗和基于生物标记的疗法日益流行，正在重塑失眠治疗的格局。消费者对天然、不易上瘾的解决方案（如基于褪黑激素的助眠剂）的需求正在推动新产品的开发。舌下片和透皮贴片等药物传递系统的进步正在扩大治疗选择，以满足不同患者的需求。製药公司和研究机构之间的策略合作正在加速非镇静性、标靶治疗的开发，进一步支持市场扩张。

主要市场驱动因素

失眠症盛行率不断上升：

主要市场挑战

长期使用的问题：

主要市场趋势

製药业的进步：

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球失眠药物治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按药物（非处方药、非处方睡眠辅助剂、非处方睡眠补充剂、处方药）
  • 依治疗（非处方安眠药、处方安眠药）
  • 按配销通路（药局、电子商务、医​​院药局、零售药局）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第 6 章：北美失眠药物治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 7 章：欧洲失眠药物治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太失眠药物治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲失眠药物治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲失眠药物治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Merck & Co Inc
• Ebb Therapeutics Inc/US
• Pfizer Inc
• Sanofi SA
• Takeda Pharmaceutical Co Ltd
• Paratek Pharmaceuticals Inc
• Electromedical Products International Inc
• Meda Pharmaceuticals Inc
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc

第 15 章：策略建议

第16章 调査会社について・免责事项

The global insomnia pharmacological treatment market was valued at USD 3.81 billion in 2024 and is projected to reach USD 5.33 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.73%. The market is experiencing significant growth, driven by the rising prevalence of sleep disorders across the globe. Factors such as increasing stress, lifestyle changes, and the growing aging population are intensifying the demand for pharmacological treatments for insomnia. This market includes a broad spectrum of prescription and over-the-counter drugs, including benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists. Pharmaceutical companies are focusing on developing safer, more effective medications to address issues related to dependency and adverse effects associated with traditional sleep aids. Regulatory approvals for novel treatments and innovations in drug formulations are further stimulating market growth, providing patients with improved efficacy and reduced side effects.

Heightened awareness about the long-term health risks of untreated insomnia is leading to more diagnoses and a growing demand for prescription-based solutions. Innovations in extended-release and dual-action formulations are improving treatment outcomes by ensuring sustained sleep throughout the night. Additionally, the growing trend toward personalized medicine and biomarker-based therapies is reshaping the landscape of insomnia treatment. Consumer demand for natural, non-habit-forming solutions, such as melatonin-based sleep aids, is driving new product development. Advances in drug delivery systems, including sublingual tablets and transdermal patches, are expanding treatment options to meet diverse patient needs. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of non-sedative, targeted therapies, further supporting market expansion.

Key Market Drivers

Increasing Prevalence of Insomnia:

In today's fast-paced, digitally connected world, achieving quality sleep has become more challenging. Insomnia, characterized by persistent difficulties in falling asleep, staying asleep, or achieving restorative sleep, is on the rise. This increase in insomnia cases significantly contributes to the growth of the global pharmacological insomnia treatment market. Work-related stress, personal pressures, and constant exposure to screens have led to a substantial rise in sleep disturbances. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2020, approximately 14.5% of U.S. adults reported trouble falling asleep, and 17.8% had difficulty staying asleep regularly, underscoring the growing demand for treatment solutions.

Key Market Challenges

Concerns Over Long-Term Use:

One of the major challenges facing the global insomnia pharmacological treatment market is the concerns associated with the long-term use of medications. Prescription drugs used for insomnia treatment, such as benzodiazepines, non-benzodiazepine hypnotics, and certain antidepressants, can pose significant risks when used over extended periods. Prolonged use can lead to tolerance, dependency, withdrawal symptoms, and cognitive impairments. Over time, patients may require higher doses to achieve the same therapeutic effects, potentially leading to misuse or addiction. Furthermore, the risk of rebound insomnia when discontinuing these medications can worsen sleep disturbances. Long-term use of sedative-hypnotic medications has also been linked to adverse health effects, including cognitive decline and an increased risk of falls, particularly among elderly patients. Regulatory agencies like the U.S. FDA and the European Medicines Agency (EMA) have raised concerns about these risks, leading to stricter guidelines and closer scrutiny of chronic insomnia management.

As awareness of these issues grows, healthcare providers are exploring alternative treatments, such as cognitive behavioral therapy for insomnia (CBT-I) and lifestyle interventions, before resorting to long-term pharmacological solutions. Pharmaceutical companies face the challenge of developing new insomnia treatments that minimize dependency risks and cognitive side effects, while maintaining their effectiveness. These concerns are influencing prescription patterns, regulatory policies, and patient preferences, thereby shaping the future trajectory of the insomnia pharmacological treatment market.

Key Market Trends

Advancements in Pharmaceuticals:

The field of sleep disorders, particularly insomnia, has long been elusive, but recent advancements in pharmaceuticals are providing new insights into effective treatment options. These innovations are transforming insomnia management, offering hope and relief to individuals who have long struggled with sleep disturbances. Modern research has led to the development of new insomnia medications that are not only more effective but also safer, with fewer adverse side effects, making them more attractive to both patients and healthcare providers.

In-depth understanding of sleep regulation mechanisms has enabled the creation of targeted therapies that address specific aspects of insomnia, such as difficulties falling or staying asleep, providing more personalized and effective treatment options. Newer drugs are reducing the risks of dependency that plagued earlier sleep medications like benzodiazepines. Furthermore, some newer insomnia treatments offer longer-lasting effects, supporting sustained and restorative sleep throughout the night, improving the overall sleep experience.

Another key area of focus is minimizing next-day impairments, such as drowsiness and cognitive deficits, allowing individuals to maintain their daily activities. Advanced insomnia medications are also addressing comorbidities such as anxiety, depression, or chronic pain, offering a holistic approach to treatment.

Key Market Players:

• Merck & Co Inc.
• Ebb Therapeutics Inc. (USA)
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Paratek Pharmaceuticals Inc.
• Electromedical Products International Inc.
• Meda Pharmaceuticals Inc.
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc.

Report Scope: This report segments the global insomnia pharmacological treatment market into various categories, including industry trends and detailed analysis of the following areas:

By Drug:

• Over-the-Counter (OTC) Drugs
• OTC Sleep Aids
• OTC Sleep Supplements
• Prescription Drugs

By Treatment:

• Over-the-Counter Sleep Aids
• Prescription Sleep Aids

By Distribution Channel:

• Drug Stores
• E-Commerce
• Hospital Pharmacies
• Retail Pharmacies

By Region:

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Italy, Spain)
• Asia-Pacific (China, Japan, India, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape: In-depth analysis of leading companies in the global insomnia pharmacological treatment market.

Available Customizations: TechSci Research offers customized reports based on specific company needs. Customization options include:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Insomnia Pharmacological Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, Prescription Drugs)
  • 5.2.2. By Treatment (Over-the-Counter Sleep Aids, Prescription Sleep Aids)
  • 5.2.3. By Distribution Channel (Drug Stores, E-Commerce, Hospital Pharmacies, Retail Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Insomnia Pharmacological Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Insomnia Pharmacological Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Insomnia Pharmacological Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Insomnia Pharmacological Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Insomnia Pharmacological Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Insomnia Pharmacological Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Insomnia Pharmacological Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Insomnia Pharmacological Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Insomnia Pharmacological Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Insomnia Pharmacological Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Insomnia Pharmacological Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Insomnia Pharmacological Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Insomnia Pharmacological Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Insomnia Pharmacological Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Insomnia Pharmacological Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Insomnia Pharmacological Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. South America Insomnia Pharmacological Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Insomnia Pharmacological Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Insomnia Pharmacological Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Insomnia Pharmacological Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Insomnia Pharmacological Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Insomnia Pharmacological Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Insomnia Pharmacological Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Insomnia Pharmacological Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Ebb Therapeutics Inc/US
• 14.3. Pfizer Inc
• 14.4. Sanofi SA
• 14.5. Takeda Pharmaceutical Co Ltd
• 14.6. Paratek Pharmaceuticals Inc
• 14.7. Electromedical Products International Inc
• 14.8. Meda Pharmaceuticals Inc
• 14.9. Purdue Pharma LP
• 14.10. Pernix Therapeutics Holdings Inc

15. Strategic Recommendations

16. About Us & Disclaimer